Additionally, both T790M mutation [68,69] and EGFR-KDD amplification [68,71] were reported in biopsies of EGFR-KDD tumour specimens post EGFRi treatment, suggesting shared resistance mechanisms with classical EGFR mutations to targeted therapy [72,73]. This evidence concerns the gene EGFR and neoplasm.